Notably, re-expression of DYNC1I1 in GBM cells reduced plasma membrane-localized SK2 and extracellular S1P formation and, strikingly, decreased tumor growth and tumor-associated angiogenesis in vivo. The gene discussed is SPHK2; the disease is glioblastoma.